4D Molecular Therapeutics (NASDAQ:FDMT) Earns Overweight Rating from Analysts at Barclays

Equities researchers at Barclays began coverage on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a report released on Monday, Marketbeat reports. The firm set an “overweight” rating on the stock.

Other equities analysts have also recently issued research reports about the company. BMO Capital Markets dropped their target price on 4D Molecular Therapeutics from $70.00 to $63.00 and set an “outperform” rating on the stock in a research report on Monday, April 1st. HC Wainwright reiterated a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Friday, March 1st. Royal Bank of Canada boosted their target price on 4D Molecular Therapeutics from $25.00 to $35.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. The Goldman Sachs Group reiterated a “buy” rating and set a $81.00 target price on shares of 4D Molecular Therapeutics in a research report on Wednesday, February 7th. Finally, Jefferies Financial Group boosted their price target on 4D Molecular Therapeutics from $30.00 to $58.00 and gave the stock a “buy” rating in a research note on Monday, April 1st. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, 4D Molecular Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $44.22.

4D Molecular Therapeutics Stock Down 5.4 %

Shares of FDMT stock opened at $25.30 on Monday. The stock has a market capitalization of $1.29 billion, a PE ratio of -9.51 and a beta of 2.87. 4D Molecular Therapeutics has a 52-week low of $9.44 and a 52-week high of $36.25. The stock’s 50-day moving average price is $29.01 and its 200 day moving average price is $20.09.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.09). The company had revenue of ($0.02) million during the quarter, compared to analyst estimates of $4.67 million. 4D Molecular Therapeutics had a negative net margin of 436.30% and a negative return on equity of 34.14%. Analysts expect that 4D Molecular Therapeutics will post -3.03 earnings per share for the current fiscal year.

Insider Activity at 4D Molecular Therapeutics

In related news, insider Scott Bizily sold 8,153 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $31.78, for a total value of $259,102.34. Following the sale, the insider now owns 1,737 shares of the company’s stock, valued at approximately $55,201.86. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, insider Scott Bizily sold 8,153 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $31.78, for a total value of $259,102.34. Following the sale, the insider now owns 1,737 shares of the company’s stock, valued at approximately $55,201.86. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO David Kirn sold 92,001 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $27.13, for a total value of $2,495,987.13. Following the completion of the sale, the chief executive officer now directly owns 1,059,153 shares in the company, valued at approximately $28,734,820.89. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 147,888 shares of company stock valued at $4,134,254. 10.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP lifted its stake in 4D Molecular Therapeutics by 4.5% in the 4th quarter. Wellington Management Group LLP now owns 180,475 shares of the company’s stock valued at $3,656,000 after buying an additional 7,753 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of 4D Molecular Therapeutics by 415.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 816,343 shares of the company’s stock worth $16,539,000 after purchasing an additional 658,069 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of 4D Molecular Therapeutics by 5.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 22,596 shares of the company’s stock worth $458,000 after purchasing an additional 1,106 shares during the period. Virtus ETF Advisers LLC lifted its stake in shares of 4D Molecular Therapeutics by 24.4% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,574 shares of the company’s stock worth $113,000 after purchasing an additional 1,095 shares during the period. Finally, Barclays PLC lifted its stake in shares of 4D Molecular Therapeutics by 47.0% during the 4th quarter. Barclays PLC now owns 108,709 shares of the company’s stock worth $2,202,000 after purchasing an additional 34,774 shares during the period. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.